Ann Clin Case Rep | Volume 6, Issue 1 | Case Report | Open Access

Euglycemic Diabetic Ketoacidosis in a Patient with Type 2 Diabetes Mellitus on Sodium- Glucose Cotransporter-2 Inhibitors Induced by COVID-19

AlSaraj F1*, Krishnareddy K2, Capatos G2 and Medhat P2

1Department of Endocrinology, Mediclinic Parkview Hospital, Dubai, UAE 2Intensive Care Unit of Mediclinic Parkview Hospital, Dubai, UAE

*Correspondance to: AlSaraj F 

Fulltext PDF

Abstract

A 47-years old lady presented to the emergency department complaining of severe symptoms of lower respiratory tract infection of three days duration. She has history of type 2 diabetes on Dapagliflozin, is one of the sodium- glucose cotransporter-2 inhibitor. Clinical, radiological and laboratory tests confirmed the diagnosis of moderate COVID-19 pneumonia and euglycemic diabetes ketoacidosis. The patient admitted to the intensive care unit for better management and discharged home after nine days of hospitalization. We reporting, COVID-19 could induce this serious metabolic abnormality. Therefore, clinicians should be aware of this complication in this current pandemic.

Keywords:

#

Citation:

AlSaraj F, Krishnareddy K, Capatos G, Medhat P. Euglycemic Diabetic Ketoacidosis in a Patient with Type 2 Diabetes Mellitus on Sodium- Glucose Cotransporter-2 Inhibitors Induced by COVID-19. Ann Clin Case Rep. 2021; 6: 1948..

Subscribe to Our Newsletter